Article Text

Download PDFPDF

684 Assay development and quantitative detection of ADI-001, a CD20-targeted γδ1 CAR T therapy, using AlloCell, a universal assay for monitoring of off-the-shelf allogeneic cell therapies
  1. Jackie Kennedy-Wilde1,
  2. Lilly Wong2,
  3. Monica Moreno1,
  4. Collin DuBois2,
  5. David Liu2,
  6. Divya Kilam2,
  7. Natali Gulbahce2,
  8. Andrew Wrong1,
  9. Monika Maleszewska2,
  10. Yining Yi1,
  11. Francesco Galimi1,
  12. Rose Lai3 and
  13. Blake T Aftab1
  1. 1Adicet Bio, Redwood City, CA, USA
  2. 2CareDx, South San Francisco, CA, USA
  3. 3University of Southern California, San Ramon, CA, USA
  • Journal for ImmunoTherapy of Cancer (JITC) preprint. The copyright holder for this preprint are the authors/funders, who have granted JITC permission to display the preprint. All rights reserved. No reuse allowed without permission.


Background Expansion and persistence of CAR-T products has historically correlated with patient outcomes. CAR-T expansion and pharmacokinetics (PK) are typically monitored by flow cytometry or by transgene qPCR, using detection reagents that are bespoke to individual products, limiting universal application across products or platforms. In monitoring allogeneic CAR-T products, these methods also usually lack capabilities for distinguishing multi-donor origin. Here, we present qualification and clinical application of a quantitative and universal solution (AlloCell) for monitoring of ADI-001, a first-in-class CD20-targeted allogeneic γδ1 CAR T cell therapy.1

Methods AlloCell was analytically validated for 2-genome-based (1 donor) and 3-genome-based (2 donors) analyses. To additionally qualify AlloCell for ADI-001 monitoring, genomic DNA (gDNA) mixtures were prepared using 1) gDNA from peripheral blood of two healthy individuals, or 2) gDNA from 2 FFPE blocks (to establish feasibility for application in solid tissues). The mixtures mimicked cell product levels of 3%, 1%, 0.3%, 0.1%, and 0.03%.

Applying this method, clinical blood samples from the Phase 1 evaluation of ADI-001 (NCT04735471)2 were processed and gDNA was extracted for analysis. gDNA samples were analyzed using the AlloCell assay workflow. Briefly, quality control (QC) was performed using Nanodrop and Qubit. Next, gDNA was used in NGS library preparation and sequenced using NextSeq technology. Sequencing data were analyzed using the AlloCell bioinformatics pipeline.

Results The levels of cell product measured for qualification closely matched the expected levels of donor-derived gDNA in cell mixtures, with a high degree of linearity (n=3, R2=1), and was reproduced in FFPE samples (n=3, R2=0.996). We observed high precision across triplicates, with CVs ranging from 0.31% for 3% mixture, to 5.3% for the 0.03% mixture, or for FFPE samples, from 0.93% for 1% mixture to 23.6% for the at the lowest bound mixture of 0.03%.

Data from ADI-001 patient samples demonstrated AlloCell’s ability to track cell product kinetics in a clinical setting and determined dose-dependent exposure for ADI-001 across four dose levels evaluated. Finally, in one patient receiving two separate and sequential doses of ADI-001, each manufactured from distinct donors, AlloCell successfully distinguished independent expansions of the first and second donor-sourced cell products.

Conclusions AlloCell was validated as a precise and sensitive analytical platform that can quantitatively monitor PK of allogeneic cell therapies. Application of AlloCell to monitor clinical exposure of ADI-001 successfully demonstrated dose-dependent expansion and persistence across multiple dose levels and resolved donor origin for distinct ADI-001 expansions associated with a multiple dosing regimen.

Trial Registration NCT04735471: A Safety and Efficacy Study of ADI-001, an Anti-CD20 Allogeneic Gamma Delta CAR-T, in Subjects With B Cell Malignancies (GLEAN-1)


  1. Nishimoto KP, Barca T, Azameera A, et al. Allogeneic CD20-targeted γδ T cells exhibit innate and adaptive antitumor activities in preclinical B-cell lymphoma models. Clin Transl Immunology. 2022;11(2):e1373. Published 2022 Feb 2. doi:10.1002/cti2.1373

  2. Neelapu SS, Stevens DA, Hamadani M, et al. A Phase I Study of ADI-001: Anti-CD20 CAR-Engineered Allogeneic Gamma Delta 1 T cells in Adults with B-cell Malignancies. Blood 2022;140(Supplement 1):4617–1619.–157400

Ethics Approval Ethics approvals have been obtained from each clinical site enrolling patients on NCT04735471, A Safety and Efficacy Study of ADI-001, an Anti-CD20 Allogeneic Gamma Delta CAR-T, in Subjects With B Cell Malignancies (GLEAN-1): Stanford University Medical Center, Stanford, CA; University of Miami-Sylvester Comprehensive Cancer Center, Miami, FL; Northside Hospital Blood and Marrow Transplant Group of Georgia, Atlanta, GA; The State University of Iowa, Iowa City, IA; Norton Cancer Institute, Louisville, KY; Baylor Scott & White Research Institute, Dallas, TX; MD Anderson Cancer Center, Houston, TX; Medical College of Wisconsin, Milwaukee, WI

Consent Informed consent was obtained from all patients prior to enrollment, treatment and sample analyses.

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.